Piper Jaffray analyst David Amsellem reiterated an Overweight-rating and boosted his price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $19.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Amphastar Pharmaceuticals (AMPH) PT Raised to $18 at JefferiesMarch 25, 2015 7:43 AM Amphastar Pharma (AMPH) Tops Q4 EPS by 7cMarch 24, 2015 4:03 PM Amphastar Pharmaceuticals Reports Revenues of $55.9 Million for the Fourth Quarter Ended December 31, 2014March 24, 2015 4:01 PM